Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma
Main Authors: | Pinato, D, Brown, M, Trousil, S, Aboagye, E, Beaumont, J, Zhang, H, Coley, H, Mauri, F, Sharma, R |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Springer Nature
2019
|
Similar Items
-
AXL receptor tyrosine kinase as a therapeutic target in NSCLC
by: Okimoto RA, et al.
Published: (2015-04-01) -
The Receptor Tyrosine Kinase AXL in Cancer Progression
by: Erinn B. Rankin, et al.
Published: (2016-11-01) -
Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma
by: Kristina Breitenecker, et al.
Published: (2023-09-01) -
Axl receptor tyrosine kinase is a regulator of apolipoprotein E
by: Wenchen Zhao, et al.
Published: (2020-05-01) -
AXL receptor tyrosine kinase: a possible therapeutic target in acute promyelocytic leukemia
by: Mariam Fatima, et al.
Published: (2021-06-01)